Ideaya Biosciences Inc (IDYA)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Ideaya Biosciences Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 6 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 35.50 $ — 72% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 48.7% above the current price.
- Consensus
- Strong Buy
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Next Reporting Date
- Expected Earnings per Share
- -1.18 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -1.49 | – | 7 | 78.40 | -1,861.60 | -122 | -123 |
| 2025: Q1 | -0.81 | – | 0 | – | – | -60 | -62 |
| 2025: Q2 | -0.88 | – | 0 | – | – | -63 | -63 |
| 2025: Q3 | 1.33 | – | 208 | – | 57.40 | 142 | 142 |
| 2025: Q4 | -0.94 | – | 11 | 55.40 | -765.70 | -91 | -91 |
| 2026: Q1 | -1.11 | – | 7 | – | -1,502.10 | -75 | -76 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
IDEAYA Biosciences, Inc., ein Präzisionsmedizin-Onkologie-Unternehmen, entwickelt gezielte Therapeutika für Patientenpopulationen, die mittels molekularer Diagnostik in den USA ausgewählt werden.
| Employees | 145 |
|---|---|
| Headquarters | South San Francisco, CA |
| Website | ideayabio.com |
| IPO Date | 23. May 2019 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Yujiro S. Hata | Founder, President, CEO & Chairman | 1974 |
| Joshua Bleharski Ph.D. | Chief Financial Officer | 1975 |
| Andres Ruiz Briseno CPA | Chief Accounting Officer | 1986 |
| Michael A. White Ph.D. | Chief Scientific Officer | 1965 |
| Douglas B. Snyder | Chief Legal Officer | 1964 |
| Darrin M. Beaupre M.D., Ph.D. | Chief Medical Officer | 1967 |
| Paul A. Barsanti Ph.D. | Chief Technology Officer | – |
| Francine Zelaya | Senior VP & Head of Human Resources | – |
| Mick O'Quigley | Senior Vice President of Medical Writing & Project Management | – |
| Daniel A. Simon | Chief Business Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 7. Jul 2026 | Ruiz Briseno Andres | Chief Accounting Officer | Sell | 9,550 | 40.01 | 382,131 |
| 7. Jul 2026 | Ruiz Briseno Andres | Chief Accounting Officer | Other | 9,550 | 12.86 | 122,813 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.